Related Experiment Video
Updated: May 5, 2026
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
P2X7 blockade attenuates mouse liver fibrosis
Changshan Huang1, Wei Yu, Hong Cui
1Department of Hepatobiliary Surgery, Henan Provincial Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
Abstract:
P2X7 is important in inflammation and tissue injury. The aim of the present study was to investigate the effect of P2X7 inhibition, using a specific inhibitor (A438079) to prevent the development of liver injury and fibrosis in a mouse model of liver fibrosis. The mouse liver fibrosis model was induced by carbon tetrachloride (CCl4). Mice received subcutaneous administration of vehicle (saline/olive oil), CCl4 or subcutaneous CCl4 and A438079. The pro‑inflammatory and pro‑fibrotic factors were determined by western blot analysis. The biochemistry, histopathology, collagen deposition and nuclear factor‑κB (NF‑κB) activity were also analyzed. Chronic CCl4 treatment resulted in liver injury and collagen accumulation. The expression levels of P2X7, pro‑inflammatory and pro‑fibrotic mediators, and the activity of NF‑κB were markedly increased. Treatment with A438079 significantly inhibited CCl4‑induced P2X7 expression, and attenuated CCl4‑induced liver injury and the inflammatory response. P2X7 blockade also significantly reduced the formation of collagen in the liver and the expression of α-smooth muscle actin and transforming growth factor‑β1. This study demonstrated that P2X7 inhibition attenuated liver injury and fibrosis in a mouse model. Thus, P2X7 is a potential novel therapeutic target for liver injury and fibrosis.
Insights
Inhibiting P2X7 receptors with A438079 reduced liver injury and fibrosis in mice. This suggests P2X7 blockade is a promising therapeutic strategy for treating liver damage and scarring.
Area of Science:
- Pharmacology
- Hepatology
- Immunology
Background:
- P2X7 receptor plays a key role in inflammation and tissue damage.
- Liver injury and fibrosis are significant health concerns with limited treatment options.
Purpose of the Study:
- To investigate the therapeutic potential of P2X7 inhibition in a mouse model of liver fibrosis.
- To evaluate the effect of A438079, a specific P2X7 inhibitor, on carbon tetrachloride-induced liver injury.
Main Methods:
- A mouse model of liver fibrosis was established using chronic carbon tetrachloride (CCl4) administration.
- Mice were treated with either vehicle or A438079 to assess the impact on P2X7 expression and related pathways.
- Biochemical, histopathological, and molecular analyses (Western blot, collagen deposition, NF-κB activity) were performed.
Main Results:
- CCl4 treatment led to significant liver injury, inflammation, fibrosis, and increased P2X7 expression.
- A438079 treatment markedly reduced P2X7 expression, liver damage, and inflammatory markers.
- P2X7 inhibition also decreased collagen deposition, α-smooth muscle actin, and transforming growth factor-β1 expression.
Conclusions:
- P2X7 receptor inhibition effectively attenuated liver injury and fibrosis in a preclinical model.
- Targeting P2X7 represents a potential novel therapeutic approach for managing liver diseases characterized by inflammation and fibrosis.
